Thompson Davis & Co’s NovoCure NVCR Stock Holding History

Thompson Davis & Co’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$20K	Hold	375	–	–	0.04%	329
2018 Q2	$12K	Hold	375	–	–	0.03%	408
2018 Q1	$8K	Buy	375 +125	+50%	+$2.69K	0.02%	428
2017 Q4	$5K	Buy	+250	New	+$4.81K	0.01%	523
2017 Q3	–	Sell	-250	Closed	-$4.91K	–	1167
2017 Q2	$4K	Buy	+250	New	+$3.23K	0.01%	886

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Thompson Davis & Co's NVCR Position: Q3 2018 in Review

Thompson Davis & Co held its NovoCure (NVCR) position steady in Q3 2018 at 375 shares worth $20K. The position accounts for 0.04% of the portfolio, ranked #329.

Thompson Davis & Co first reported a position in NVCR in Q2 2017 and has held it in 5 quarters since. 176 funds tracked by Wall St. Rank hold NVCR as of Q3 2018.

Thompson Davis & Co held 375 shares of NovoCure worth $20K as of Q3 2018.
Thompson Davis & Co left its NovoCure share count unchanged in Q3 2018.
NovoCure made up 0.04% of Thompson Davis & Co's portfolio in Q3 2018, its #329 holding.
Thompson Davis & Co first reported a position in NovoCure in Q2 2017 and has held it in 5 quarters since.
176 funds tracked by Wall St. Rank held NovoCure as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.